Global Bioburden Testing Market Size, Share, Opportunities And Trends By Products Used (Consumables, Culture Media, Kits And Reagents, Others), By Instruments (PCR, Microscopes, Others), By Applications (Raw Material Testing, Medical Devices Testing, In-process Testing, Others), By End Users (Pharmaceuticals And Biopharmaceutical Manufacturers, CMOs, Medical Device Manufacturers) And By Geography - Forecasts From 2019 To 2024

  • Published : Mar 2020
  • Report Code : KSI061611930
  • Pages : 114

The global Bioburden Testing market is expected to reach $XX billion by 2023 from $XX billion in 2017 growing at a CAGR of XX%. Bioburden testing, also called microbial enumeration testing (MET) is carried out to determine the number of microbes on any surface of medical devices or ingredients for pharmaceutical use. Producing safe products is a core goal of all medical device and pharmaceutical manufacturers and bioburden testing is a key component in achieving that goal. The bioburden testing performed to measure the total number of viable microorganisms on a medical device, and then use the number to determine the most appropriate parameters for its final sterilization. The market is expected to show a significant growth at a CAGR of XX% during the forecast period. Growth may be attributed to the rise in the pharmaceutical and medical device industry coupled with stringent regulatory compliance. High frequency of product recall due to microbial contamination will also boost the market for bioburden testing through to 2023. However, High cost of the bioburden testing instruments coupled with time consuming approval process might restrain the growth of the market during the given time frame.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical region. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global Bioburden Testing market value chain. Last step involves complete market engineering which includes analysing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global Bioburden Testing market.

Major industry players profiled as part of the report are SGS SA, Thermo Fisher Scientific and Becton, Dickinson, and Company among others.

Segmentation

By Products Used

Consumables

Culture Media

Kits and Reagents

Others


By Instruments

PCR

Microscopes

Others


By Applications

Raw Material Testing

Medical Devices Testing

In-process Testing

Others


By End Users

Pharmaceuticals and Biopharmaceutical Manufacturers

CMOs

Medical Device Manufacturers


By Geography

North America

United States

Canada

Others


South America

Brazil

Argentina

Others


Europe

United Kingdom

Germany

France

Others


Middle East and Africa

Saudi Arabia

UAE

Israel

Others


Asia Pacific

China

India

Australia

South Korea

Others


Key questions answered by the report

What will be the global Bioburden Testing market size from 2018 to 2023?

How are the major drivers and restraints affecting the global Bioburden Testing market growth and the opportunities which exist for key vendors?

Which segment and region will drive or lead the market growth and why?

A comprehensive analysis of competitive landscape and key market participants’ behaviour

Key strategies being adopted by vendors, with in-depth analysis along with their impact on competition and market growth


1. Introduction
1.1. Market Definition
1.2. Scope of the Study
1.3. Currency
1.4. Assumptions
1.5. Base, and Forecast Years Timeline
2. Research Methodology
2.1. Research Design
2.2. Secondary Sources
2.3. Validation
3. Key Findings of the Study
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities and Market Trends
4.4. Market Segmentation
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Industry Value Chain Analysis
4.7. Industry Regulations
4.8. Scenario Analysis
5. Global Bioburden Testing Market Forecast by Products Used 
5.1. Consumables
5.1.1. Culture Media
5.1.2. Kits and Reagents
5.1.3. Others
5.2. Instruments
5.2.1. PCR
5.2.2. Microscopes
5.2.3. Others
6. Global Bioburden Testing Market Forecast by Application
6.1. Raw Material Testing
6.2. Medical Devices Testing
6.3. In-process Testing
6.4. Others
7. Global Bioburden Testing Market Forecast by End Users
7.1. Pharmaceuticals and Biopharmaceutical Manufacturers
7.2. CMOs
7.3. Medical Device Manufacturers
8. Global Bioburden Testing Market Forecast by Geography 
8.1. North America
8.1.1. The U.S
8.1.2. Canada
8.1.3. Mexico
8.1.4. Others
8.2. South America
8.2.1. Brazil 
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. U.K.
8.3.2. France
8.3.3. Germany
8.3.4. Italy
8.3.5. Others
8.4. Middle East and Africa
8.4.1. Saudi Arabia
8.4.2. UAE
8.4.3. Israel
8.4.4. Others
8.5. Asia Pacific 
8.5.1. China
8.5.2. India
8.5.3. Australia
8.5.4. South Korea
8.5.5. Others 
9. Competitive intelligence
9.1. Market Share Analysis
9.2. Strategies of Key Players
9.3. Recent Investments and Deals
10. Company Profiles
10.1. Merck
10.1.1. Overview 
10.1.2. Financials
10.1.3. Product and Services
10.1.4. Recent Developments
10.2. Pacific BioLabs Inc. 
10.2.1. Overview 
10.2.2. Financials
10.2.3. Product and Services
10.2.4. Recent Developments
10.3. Mettler Toledo
10.3.1. Overview 
10.3.2. Financials
10.3.3. Product and Services
10.3.4. Recent Developments
10.4. Charles River
10.4.1. Overview 
10.4.2. Financials
10.4.3. Product and Services
10.4.4. Recent Developments
10.5. Rapid Micro Biosystems, Inc.
10.5.1. Overview 
10.5.2. Financials
10.5.3. Product and Services
10.5.4. Recent Developments
10.6. Thermo Fisher Scientific
10.6.1. Overview 
10.6.2. Financials
10.6.3. Product and Services
10.6.4. Recent Developments
10.7. WuXi AppTec
10.7.1. Overview 
10.7.2. Financials
10.7.3. Product and Services
10.7.4. Recent Developments
10.8. Becton, Dickinson, and Company
10.8.1. Overview 
10.8.2. Financials
10.8.3. Product and Services
10.8.4. Recent Developments
10.9. SGS SA
10.9.1. Overview 
10.9.2. Financials
10.9.3. Product and Services
10.9.4. Recent Developments
10.10. Nelson Laboratories, LLC
10.10.1. Overview 
10.10.2. Financials
10.10.3. Product and Services
10.10.4. Recent Developments

Merck

Pacific BioLabs Inc.

Mettler Toledo

Charles River

Rapid Micro Biosystems, Inc.

Thermo Fisher Scientific

WuXi AppTec

Becton, Dickinson, and Company

SGS SA

Nelson Laboratories, LLC